FindTrial
Sign In

Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging

Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029955
Enrollment
Unknown
Registered
2020-02-17
Start date
2020-03-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.
Index test:First&#32
pass&#32
perfusion&#32
imaging&#32
parameters&#32
(slope,&#32
tip,&#32
PT)&#32
and&#32
delayed&#32
enhancement&#32
ratio&#32
(%)
&#32
quantitative&#32
T1&#32
\&#32
T2&#32
values,&#32

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV and the Chinese medicine authority; 2. No contraindications for MR examination; 3. understand the potential risks / benefits, patients or guardians agree to participate in the study, understand all the study procedures, agree the plan of follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with congenital heart disease, primary and other secondary cardiomyopathy, severe arrhythmia, frequent atrial fibrillation, and serious image quality artifacts; 2. Contraindications of MRI: there are ferromagnetic metal foreign bodies in the body (such as cardiac pacemaker, nerve stimulator, artificial metal heart valve, aneurysm clip, intraocular metal foreign body, inner ear implant, metal prosthesis, metal prosthesis, metal joint, etc.); see the informed consent of enhanced MRI for details; 3. The patients with claustrophobia had recently developed allergic diseases such as measles and allergic dermatitis; 4. Contraindications of gadolinium contrast agent: estimated glomerular filtration rate (EGFR) <30 ml/min/1.73 m2; previous adverse reactions or other drug allergy history of gadolinium contrast agent injection.

Design outcomes

Primary

MeasureTime frame
First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;—

Secondary

MeasureTime frame
biomarker of myocardial injury;—

Countries

China

Contacts

Public ContactYing-kun Guo

West China Second University Hospital, Sichuan University

gykpanda@163.com+86 18180609256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026